Age-related macular degeneration is one of the most common causes of vision loss among older adults, and its advanced form, geographic atrophy, slowly destroys the central retina. Patients lose the ability to read, recognize faces and navigate familiar rooms, and no existing therapy restores that tissue. For more than a decade, researchers have argued that an implant able to substitute for lost photoreceptors could return a measure of that function, though the engineering has remained difficult.
The technology inside Science Corporation's device began in the Stanford lab of Daniel Palanker and was later developed by the French company Pixium Vision. Science bought the program in 2024 after Pixium went into liquidation, inheriting both the hardware and the clinical history behind it. The company now describes the product, called PRIMA, as the first brain-computer interface to receive a CE mark for restoring form vision, meaning the ability to read letters, numbers and words.
Science Corporation itself was founded in 2021 by Max Hodak, who had previously served as president of Elon Musk's Neuralink. Its founding ambition was never limited to vision. The company has described a longer-term bio-hybrid sensor that would combine cultured neurons with silicon, an interface meant to integrate engineered cells with the brain's own circuits.
On November 17, 2026, the company announced a $400 million Series D, the largest single round in its history. People familiar with the deal told TechCrunch that the financing valued Science at $3.5 billion, and the company said the new capital brings total funds raised since its founding to more than $900 million. The money is intended to accelerate the European rollout of PRIMA and to prepare a launch in the United States through an uncommon regulatory pathway.
Key Facts
The round was led by Khosla Ventures and included the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. SiliconANGLE reported on November 17, 2026 that the Ackman Oxman Institute's participation is notable because it is one of the brain research center's first ventures since Bill Ackman and Neri Oxman established it earlier this year. Science did not disclose the valuation itself. TechCrunch reported on November 17, 2026 that the round valued the company at $3.5 billion, a figure Bloomberg also reported, against $1.5 billion after a $230 million Series C announced on March 5, 2026. Securities.io reported on November 17, 2026 that the Series C had lifted total capital invested to about $490 million, so the new round roughly doubles the cumulative figure to more than $900 million.
PRIMA is a two-millimeter by two-millimeter chip, just 30 micrometers thick, placed under the retina. It carries 378 pixels, each with a tiny electrode, and pairs with glasses fitted with a forward-facing camera. The camera's lens filters interference such as strong sunlight and projects near-infrared light into the eye, which the implant converts into electrical stimulation of surviving retinal cells. A zoom feature magnifies letters for reading.
Science commercially launched PRIMA in Europe on July 22, 2026, after the certification body DEKRA granted a CE mark under the EU Medical Device Regulation, authorizing sales across 30 European countries. SiliconANGLE reported on November 17, 2026 that several patients in Germany have already received implants and that dozens of additional surgical procedures are scheduled. Two of those German patients paid commercially, Bloomberg reported, and the company expects to make the device available in Italy, France and the UK in the coming months, including to cash-paying patients at a dedicated unit at Moorfields Private Eye Hospital in London, at a price it has not disclosed.
The clinical evidence rests on the PRIMAvera trial. Inside BCI reported on November 17, 2026 that the multicenter study implanted 38 patients across 17 clinical sites in five European countries. At 36 months, 27 patients were evaluable for safety and 18 for efficacy, and those 18 read on average 29 more letters on the ETDRS chart than before surgery, up from a mean improvement of 24.5 letters at 12 months. Fourteen of the 18, or 78 percent, gained at least 15 letters, equivalent to logMAR 0.3. There was no new safety signal between 12 and 36 months, serious adverse events were concentrated in the first six months after surgery, three occurred after month 12, and none were attributed to the device alone. The results were presented at EURETINA in Vienna and have not yet been published in a journal.
In the United States, Science is not pursuing a conventional premarket approval. In July 2026 it announced two Humanitarian Use Device designations, one for patients blinded in both eyes by advanced geographic atrophy and one for Stargardt disease, a condition Hodak said at TechCrunch Disrupt is now being trialled. The designations are prerequisites, not approvals. Science still needs the Humanitarian Device Exemption itself, and that route caps profit-making sales at 8,000 devices a year.
Analysis
The valuation jump is worth examining first. A move from $1.5 billion in March to $3.5 billion in November, more than double in eight months, on a device that has treated a handful of commercial patients in one country, is not a bet on near-term revenue. What this really means is that investors are pricing a regulatory platform and a manufacturing pipeline, not a single implant. The CE mark, the two US designations and the trial data function as a stack of de-risking events, and each one narrows the range of outcomes that could still go to zero.
The HDE route is the second thing to weigh. A ceiling of 8,000 profitable devices a year in the US is a real constraint, and it is deliberate: the pathway exists for technologies treating rare conditions and Science had to convince the FDA that advanced macular degeneration in both eyes is uncommon enough to qualify. That argument is defensible on the epidemiology, but it means the American market will not be a volume business for years. Europe, where the CE mark covers 30 countries and the device is already on sale, is where revenue has to come from in the near term.
There is also a quiet signal in the London arrangement. Offering PRIMA to patients who pay out of pocket at a dedicated private unit, without publishing a price, is a way to test willingness to pay before national reimbursement decisions are made. If the private channel sustains demand, Science gains a revenue base that does not depend on any single health system's budget cycle.
Against that, the biohybrid program remains a research bet. It has been tested only on animals, and the first human trials are being designed with Yale neurosurgery professor Murat Gunel, who has said the approach could offer potential treatments for Parkinson's disease and other brain injuries and illnesses. Science hopes to launch those trials within 16 months. The new capital is explicitly meant to fund substantial further investment in that program.
Why It Matters
For patients, the practical significance is that a therapy with no approved alternative is now moving through commercial channels rather than sitting in a trial protocol. People blinded by advanced geographic atrophy have had nothing to buy. The PRIMAvera numbers, 29 letters on average at three years and 78 percent of evaluable patients gaining at least 15 letters, describe a functional gain rather than a laboratory curiosity, even allowing for the fact that the efficacy cohort shrank to 18 patients.
For the brain-computer interface field, the round is a financing precedent. Most neurotech companies raise against animal data and early feasibility studies. Science raised against a CE marked commercial product, a US designations package and a prospective manufacturing build-out, and it did so at a valuation more than double its last round. That is a template other device makers will try to copy.
For regulators, the HDE pathway is being tested as a launch route rather than a last resort. Using it for a condition as widespread as macular degeneration, albeit narrowed to bilateral advanced disease, will draw scrutiny. How the FDA handles the exemption application will shape whether other implant makers treat the pathway as viable for first commercialization in the United States.
Next Up
Hodak has said he expects US commercial availability in the first half of 2027, which means the exemption application is the gating item. Before that, Science plans to extend PRIMA into Italy, France and the UK, add surgical capacity in Germany and build out manufacturing and operational infrastructure with the new capital. The company has not disclosed pricing, and that gap will matter as reimbursement discussions begin in each European market.
The biohybrid program is the longer arc. Animal testing has advanced to the point where human trial design is underway with Gunel at Yale, and the company is targeting a first human study within 16 months. If that slips, the vision business still carries the company. If it proceeds, Science will be running two very different regulatory and scientific programs at once, which is precisely the kind of ambition that a $900 million capital base is meant to make possible.
Comments (0)
Log in or sign up to leave a comment.
No comments yet. Be the first to share your thoughts.